For all enquiries call: 0845 600 9997

Assisted Conception

IVF (In-Vitro Fertilisation) This is the most used assisted conception technique worldwide. IVF literally means fertilisation "in-glass", hence the origin of the name "test tube baby". For IVF, eggs are collected from the ovaries and then put together with sperm to fertilise in a laboratory dish before being transferred into the uterus (womb).

Ovarian stimulation protocol IVF involves taking daily fertility drugs (hMG or recombinant FSH or recombinant FSH/LH with or without GnRH agonist or antagonist) to stimulate the ovaries to produce a high number of oocytes (eggs). The recruitment and development of follicles, which contain the eggs, is tracked by regular transvaginal ultrasound scans and sometimes blood tests. When at least three follicles are mature (greater than 17mm in diameter) a hormone injection (hCG) is given to ripen the eggs. Egg collection is performed generally under ultrasound guidance, and very seldom using laparoscopy 34-36 hours later. The egg collection procedure takes about 20 minutes. The ovarian stimulation protocol is individualised to maximise the chances of success while reducing the risks, complications and possibly the costs of treatment.

Natural cycle Sometimes it is possible to proceed to IVF without using any drugs for ovarian stimulation. In most cases only one or two eggs are collected but immature eggs can be matured in vitro before being fertilised. In most cases only one healthy embryo is available for transfer. Usually there are not enough embryos to be stored. Some people argue that using "natural cycle IVF" the endometrium (lining of the womb) may be more receptive to the implanting embryos.

What is IVF? Once collected the eggs are placed in a laboratory dish, mixed with the sperm, which in most cases has been produced on the same day, and left overnight to fertilise. Following fertilisation, one or two embryos are transferred into the uterus through the cervix using a fine and thin tube called catheter. The healthy embryos can be transferred two to five days after fertilisation. Embryo transfer may be done under ultrasound guidance. Any good quality suitable remaining embryos may be frozen for future use.

Who are the candidates for IVF? a) women whose fallopian tubes are blocked, damaged or absent b) men whose sperm is moderately abnormal (count and/or motility) c) couples in which previous IUI treatment cycles have failed d) couples who are known to be at risk of genetic disease or who have already had a child with a serious genetic disease and require preimplantation genetic diagnosis (PGD) e) women with a history of severe pelvic endometriosis with altered pelvic anatomy because of scarring and adhesions f) women who have hormone imbalance and require high doses of fertility drugs The success rate of IVF measured as live birth rate can be as high as 40% per cycle with fresh embryos and up to 25% with frozen embryos.

Risks and complications of IVF

Failure of treatment -- this can result from cycle cancellation because of no response or over-response to stimulation drugs, failure to collect eggs, failure to fertilize eggs, failure of the embryos to develop normally and failure of implantation. Failure of treatment can result in emotional strain, psychological stress and depression, and some couples may require psychological counseling. Risks associated with egg collection -- discomfort, bleeding, infection and injury to organs (bladder and bowel). Multiple pregnancy -- more than one fetus grows at any one time in the uterus (womb) after the transfer of two or more embryos. This is the single greatest complication of IVF treatment. Although the prospect of twin or triplets may seem attractive to some couples, high order of multiple pregnancies are associated with increased risks of maternal and fetal complications throughout pregnancy. In addition, multiple pregnancies place enormous strains for the parents including financial difficulties, emotional distress and physical exhaustion. Ovarian hyperstimulation syndrome (OHSS) -- potentially a very serious condition which result from over-stimulation of the ovaries following treatment with fertility drugs. Several follicles develop in each of the ovaries and fluid collects in the abdomen. In severe cases (1-2%) fluid may fill the entire abdominal cavity and the chest. Admission to the hospital may be required and IVF treatment abandoned in that cycle. Ectopic pregnancy -- when an embryo develops and implants outside the womb, generally into the fallopian tube. Women undergoing IVF treatment because of problems with their tubes have a greater risk of having an ectopic pregnancy. This can be a serious condition and admission to the hospital may be required.

GLOSSARY -- Hum Reprod 2009, 24:2683-87

Assisted hatching: an in vitro procedure in which the zona pellucida of an embryo is either thinned or perforated by chemical, mechanical or laser methods to assist separation of the blastocyst.

Assisted reproductive technology (ART): all treatments or procedures that include the in vitro handling of both human oocytes and sperm, or embryos, for the purpose of establishing a pregnancy.  This includes, but is not limited to, in vitro fertilisation and embryo transfer, gamete intrafallopian transfer, zygote intrafallopian transfer, tubal embryo transfer, gamete and embryo cryopreservation, oocytes and embryo donation, and gestational surrogacy. ART does not include assisted insemination (artificial insemination) using sperm from either a woman's partner or a sperm donor.

Biochemical pregnancy (preclinical spontaneous abortion/miscarriage): a pregnancy diagnosed only by the detection of hCG in serum or urine and does not develop into a clinical pregnancy.

Blastocyst: an embryo, five or six days after fertilisation with inner cell mass, outer layer of trophoectoderm and a fluid-filled blastocoele cavity.

Cancelled cycle: an ART cycle in which ovarian stimulation or monitoring has been carried out with the intention to treat, but did not proceed to follicular aspiration or, in the case of a thawed embryo, to embryo transfer.

Clinical pregnancy: a pregnancy diagnosed by ultrasonographic visualisation of one or more gestational sacs or definitive clinical signs of pregnancy.  It includes ectopic pregnancy. Multiple gestational sacs are counted as one clinical pregnancy.

Clinical pregnancy rate: the number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles or embryo transfer cycles. When clinical pregnancy rates are given, the denominator (initiated, aspirated or embryo transfer cycles) must be specified.

Clinical pregnancy with fetal heart beat: the pregnancy diagnosed by ultrasonographic or clinical documentation of at least one fetus with heart beat.  It includes ectopic pregnancy.

Congenital anomalies: all structural, functional and genetic anomalies diagnosed in aborted fetuses, at birth or in the neonatal period.

Controlled ovarian stimulation (COS) for ART: pharmacological treatment in which women are stimulated to induce the development of multiple ovarian follicles to obtain multiple oocytes at follicular aspiration.

Controlled ovarian stimulation (COS) for non-ART cycles: pharmacological treatment for women in which the ovaries are stimulated to ovulate more than one oocyte.

Cryopreservation: the freezing or vitrification and storage of gametes, zygotes, embryos or gonadal tissue.

Cumulative delivery rate with at least one live born baby: the estimated number of deliveries with at least one live born baby resulting from one initiated or aspirated ART cycle including the cycle when fresh embryos are transferred, and subsequent frozen/thawed ART cycles. This rate is used when less than the total number of embryos fresh and/or frozen/ thawed have been utilised from one ART cycles.  The delivery of a singleton, twin or other multiple pregnancy is registered as one delivery. 

Delivery: the expulsion or extraction of one or more fetuses from the mother after 20 completed weeks of gestational age.

Delivery rate after ART treatment per patient: the number of deliveries with at least one live born baby per patient following a specified number of ART treatments.

Delivery rate: the number of deliveries expressed per 100 initiated cycles, aspiration cycles or embryo transfer cycles. When delivery rates are given, the denominator (initiated, aspirated or embryo transfer cycles) must be specified. It includes deliveries that resulted in the birth of one or more live babies and/or stillborn babies. The delivery of a singleton, twin or other multiple pregnancy is registered as one delivery.

Early neonatal death: death of a live born baby within 7 days of birth.

Ectopic pregnancy: a pregnancy in which implantation takes place outside the uterine cavity (womb).

Elective embryo transfer: the transfer of one or more embryos, selected from a larger cohort of available embryos.

Embryo: the product of the division of the zygote to the end of the embryonic stage, eight weeks after fertilisation.

Embryo donation: the transfer of an embryo resulting from gametes (sperm and oocytes) that did not originate from the recipient and her partner.

Embryo recipient cycle: an ART cycle in which a woman receives zygote(s) or embryo(s) form donor(s)

Embryo/fetus reduction: a procedure to reduce the number of viable embryos or fetuses in a multiple pregnancy.

Embryo transfer (ET): the procedure in which one or more embryos are placed in the uterus or Fallopian tube.

Embryo transfer cycle: an ART cycle in which one or more embryos are transferred into the uterus (womb) or Fallopian tube.

Extremely low birth weight: birth weight less than 1,000 grams.

Extremely preterm birth: a live birth or stillbirth that takes place after at least 20 but less than 28 completed weeks of gestational age.

Fertilisation: the penetration of the ovum by the sperm and combination of their genetic material resulting in the formation of a zygote.

Fetal death (stillbirth): death prior to the complete expulsion or extraction from its mother of a product of fertilisation, at or after 20 completed weeks of gestational age. The death is indicated by the fact that after such separation, the fetus does not breathe or show any other evidence of life such as heart beat, umbilical cord pulsation, or definite movement of voluntary muscles.

Fetus: the product of fertilisation from completion of embryonic development, at eight completed weeks after fertilisation, until abortion or birth.

Frozen/thawed embryo transfer cycle (FET): an ART procedure in which cycle monitoring is carried out with the intention of transferring a frozen/thawed embryo or frozen/thawed embryos. A FET cycle is initiated when specific medication is provided or cycle monitoring is started with the intention to treat.

Frozen/thawed oocytes cycle: an ART procedure in which cycle monitoring is carried out with the intention of fertilising thawed oocytes and performing embryo transfer.

Full-term birth: a live birth or stillbirth that takes place between 37 competed and 42 completed weeks of gestational age.

Gamete intrafallopian transfer (GIFT): an ART procedure in which gametes (oocytes and spermatozoa) are transferred in to the Fallopian tubes.

Gestational age: age of an embryo or fetus calculated by adding 2 weeks (14 days) to the number of completed weeks since fertilisation. For frozen/thawed embryo transfers, an estimated date of fertilisation is computed by subtracting the embryo age at freezing from the transfer date of the FET cycle.

Gestational carrier (surrogate): a woman who carries a pregnancy with an agreement that she will give the offspring to the intended parent(s). Gametes can originate from the intended parent(s) and /or a third party (or parties).

Gestational sac: a fluid-filled structure associated with early pregnancy, which may be located inside or outside the uterus (in case of an ectopic pregnancy).

Hatching: the process by which an embryo at the blastocyst stage (day 5) separates from the zona pellucida.

High-order multiple: a pregnancy or delivery with three or more fetuses or neonates.

Implantation: the attachment and subsequent penetration by the zona-free blastocysts (usually in the endometrium) that starts five to seven days after fertilization.

Implantation rate: the number of gestational sacs observed, divided by the number of embryos transferred.

In vitro fertilization (IVF): an ART procedure that involves extra-corporeal fertilization.

Induced abortion: the termination of a clinical pregnancy, by deliberate interference that takes place before 20 completed weeks of gestational age (18 weeks post fertilization) or, if gestational age is unknown, of an embryo/fetus less than 400 grams.

Infertility (clinical definition): a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse.

Initiated cycle: an ART cycle in which the woman receives specific medication for ovarian stimulation, or monitoring in the case of natural cycles, with the intention to treat, irrespective of whether or not follicular aspiration is attempted.

IntraCytoplasmic Sperm Injection (ICSI): a procedure in which a single sperm is injected into the oocyte cytoplasm.

Live birth: the complete expulsion or extraction from its mother of a product of fertilization, irrespective of the duration of the pregnancy, which, after such separation, breathes or shows any other evidence of life such as heart beat, umbilical cord pulsation, or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached.

Live birth delivery rate: the number of deliveries that resulted in at least one live born baby expressed per 100 initiated cycles, aspiration cycles or embryo transfer cycles. When delivery rates are given, the denominator (initiated, aspirated, or embryo transfer cycles) must be specified.

Low birth weight: Birth weight less than 2,500 grams.

Medically Assisted Reproduction (MAR): reproduction brought about through ovulation induction, controlled ovarian stimulation, ovulation triggering, ART procedures, and intrauterine, intracervical, and intravaginal insemination with semen of husband/partner or donor.

MESA: Microsurgical Epididymal Sperm Aspiration.

MESE: Microsurgical Epididymal Sperm Extraction.

Micromanipulation: a technology that allows micro-operative procedures to be performed on the sperm, oocyte, zygote or embryo.

MicroTESE: Microsurgical Testicular Sperm Extraction.

Mild ovarian stimulation for IVF: a procedure in which the ovaries are stimulated with either gonadotrophins and/or other compounds, with the intent to limit the number of oocytes obtained for IVF to fewer than seven.

Missed abortion (miscarriage): a clinical abortion (miscarriage) where the embryo(s) or fetus(es) is/are non-viable and is/are not expelled spontaneously from the uterus.

Modified natural cycle: and IVF procedure in which one or more oocytes are collected from the ovaries during a spontaneous menstrual cycle. Drugs are administered with the sole purpose of blocking the spontaneous LH surge and/or inducing final oocyte maturation.

Multiple gestation/birth: a pregnancy/delivery with more than one fetus/neonate.

Natural IVF cycle: an IVF procedure in which one or more oocytes are collected from the ovaries during a spontaneous menstrual cycle without any drug use.

Neonatal death: death of a live born baby within 28 days of birth.

Neonatal period: the time interval that commences at birth and ends 28 completed days after birth.

Oocyte donation cycle: a cycle in which oocytes are collected from a donor for clinical application or research.

Oocyte recipient cycle: an ART cycle in which a woman receives oocytes from a donor.

Ovarian Hyper Stimulation Syndrome (OHSS): an exaggerated systemic response to ovarian stimulation characterised by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distension, ovarian enlargement and respiratory, haemodynamic and metabolic complications.

Ovarian torsion: the partial or complete rotation of the ovarian vascular pedicle that causes obstruction to ovarian blood flow, potentially leading to necrosis of ovarian tissue.

Ovulation induction (OI): pharmacological treatment of women with anovulation or oligo-ovulation with the intention of inducing normal ovulatory cycles.

Perinatal mortality: fetal or neonatal death incurring during late pregnancy (at 20 completed weeks of gestational age and later), during childbirth and up to 7 completed days after birth.

PESA: Percutaneous Epididymal Sperm Aspiration.

Post-term birth: a live birth or stillbirth that takes place after 42 completed weeks of gestational age

Preimplantation Genetic Diagnosis (PGD): analysis of polar bodies, blastomeres or trophectoderm from oocytes, zygotes or embryos for the detection of specific genetic, structural and/or chromosomal alterations.

Prelimplantation Genetic Screening (PGS): analysis of polar bodies, blastomeres or trophectoderm from oocytes, zygotes or embryos for the detection of aneuploidy, mutation and/or DNA rearrangement.

Preterm birth: a live birth or stillbirth that takes place after at least 20 but before 37 completed weeks of gestational age.

Recurrent spontaneous abortion/miscarriage: the spontaneous loss of two or more clinical pregnancies.

Reproductive surgery: surgical procedures performed to diagnose, conserve, correct and/or improve reproductive function.

Severe Ovarian Hyper Stimulation Syndrome: severe OHSS is defined to occur when hospitalisation is indicated (see definition of Ovarian Hyper Stimulation Syndrome).

Small for gestational age: birth weight less than 2 standard deviations below the mean or less than the 10th centile according to local intrauterine growth charts.

Sperm recipient cycle: an ART cycle in which a woman receives sperm from a donor who is someone other than her partner.

Spontaneous abortion/miscarriage: the spontaneous loss of a clinical pregnancy that occurs before 20 completed weeks of gestational age (18 weeks post fertilization) or, if gestational age is unknown, the loss of an embryo/fetus of less than 400 grams.

TESA: Testicular Sperm Aspiration.

TESE: Testicular Sperm Extraction.

Total delivery rate with at least one live birth: the estimated total number of deliveries with at least one live born baby resulting from one initiated or aspirated ART cycle including all fresh cycles and all frozen/thawed ART cycles. This rate is used when all of the embryos fresh and/or frozen/thawed have been utilised from one ART cycle. The delivery of a singleton, twin or other multiple pregnancies is registered as one delivery.

Vanishing Sac(s) or embryo(s): spontaneous disappearance of one or more gestational sacs or embryos in an ongoing pregnancy, documented by ultrasound.

Very low birth weight: birth weight less than 1,500 grams.

Very preterm birth: a live birth or stillbirth that takes place after at least 20 but less than 32 completed weeks of gestational age.

Vitrification: an ultra-rapid cryopreservation method that prevents ice formation within the suspension which is converted to a glass-like solid.

Zygote: a diploid cell resulting from the fertilization of an oocyte by a sperm, which subsequently divides to form an embryo.

Zygote Intra-Fallopian Transfer (ZIFT): a procedure in which zygote(s) is/are transferred into the fallopian tube.

ICSI (Intra-Cytoplasmic Sperm Injection)

This is a more sophisticated technique as compared to conventional IVF. Up to the point of egg collection, ICSI and IVF do not differ.

Ovarian stimulation protocol

Daily fertility drugs (hMG or recombinant FSH or recombinant FSH/LH with or without GnRH agonist or antagonist) are necessary to stimulate the ovaries to produce a high number of oocytes (eggs). The recruitment and development of follicles, which contain the eggs, is tracked by regular transvaginal ultrasound scans and sometimes blood tests. When at least three follicles are mature (greater than 17mm in diameter) a hormone injection (hCG) is given to ripen the eggs. Egg collection is performed generally under ultrasound guidance, and very seldom using laparoscopy 34-36 hours later. The egg collection procedure takes about 20 minutes.
The ovarian stimulation protocol is individualised to maximise the chances of success while reducing the risks, complications and possibly the costs of treatment.

Natural cycle

Sometimes it is possible to proceed to egg collection without using any drugs for ovarian stimulation. In most cases only one or two eggs are collected but immature eggs can be matured in vitro before being fertilised. In most cases only one healthy embryo is available for transfer. Usually there are not enough embryos to be stored. Some people argue that using "natural cycle" the endometrium (lining of the womb) may be more receptive to the implanting embryos.

What does ICSI involve?

This assisted conception technique involves injecting a single sperm directly into the centre (cytoplasm) of an egg, which when fertilised is transferred in to the uterus (womb) using conventional embryo-transfer methods. ICSI is carried out using a piece of equipment known as "micromanipulator".
In details, the ICSI injection process involves holding an egg by gentle suction with a microscopic tube and then picking up and injecting a sperm into the centre of this egg using a very thin glass pipette. The eggs are then left overnight in the incubator for fertilisation. The next day the embryologist assesses the eggs for fertilisation.

Who are the candidates for ICSI?

a) couples whose male partner has severe sperm abnormalities with low sperm count, reduced sperm motility, an high number of sperm with an abnormal appearance, or where there are antisperm antibodies, that cause sperm to stick together
b) couples who have had failed IVF treatment because of failed fertilization
c) couples whose male partner has no sperm in the ejaculate but sperm can be retrieved surgically from the testes using techniques like percutaneous sperm aspiration (PESA) or testicular sperm extraction (TESE)
d) women who use frozen eggs

Like IVF, the success rate of ICSI measured as live birth rate can be as high as 40% per cycle with fresh embryos and up to 25% with frozen embryos.

Risks and complications of ICSI

The risks associated with egg collection, the risk of ectopic pregnancy and the risk of ovarian hyperstimulation syndrome (OHSS) are the same as IVF. The risk of multiple pregnancy after ICSI is the same as IVF, but it has been reported an increased incidence of monozygotic twinning with ICSI. The risk of failure of treatment in terms of failed fertilization is lower with ICSI as compared to IVF.

Regarding any genetic risks, it has been reported that the risks of birth defects in children conceived after ICSI may be higher than natural conception. Studies in the literature suggest that the increased incidence may be attributed to parental characteristics, including the casue of subfertility and chromosomal abnormalities, rather than the use of assisted reproductive technology itself. There is a 1.4-2.0 fold increase in the rate of birth defects following assisted conception as compared to natural conception. Children born after ICSI have a higher rate of chromosomal abnormalities either inherited from paternal structural chromosomal abnormalities or de-novo. A proportion of men with severe sperm problems have a genetic basis for this, usually an abnormality of the Y chromosome. This is likely to be inherited by male offspring after ICSI. Children conceived by ICSI appear to have more congenital abnormalities, particularly urogenital defects, which can be surgically corrected. Overall the data in the literature are rather reassuring for the long-term consequences of children born after IVF/ICSI.

IUI (Intrauterine Insemination)

What is IUI?

This is a relatively simple fertility treatment that involves inserting prepared sperm into the uterus (womb) around the time of ovulation (release of an egg) using a very fine tube known as a catheter. IUI is usually the first line treatment for unexplained subfertility. It is necessary that the fallopian tubes are patent (healthy) and the sperm is normal before embarking upon IUI.

The majority of clinicians prefer to stimulate a woman's egg production by prescribing fertility drugs to be taken during the first part of the monthly cycle. The recruitment and development of follicles, which contain the eggs, is tracked by transvaginal ultrasound scans. When a follicle is mature (greater than 17mm in diameter) a hormone injection is given to ripen and release the egg. Insemination is carried out 34-36 hours later. On the day, the man's sperm is prepared so to select the best possible sample to be deposited through a sterile catheter into the cavity of the womb. This process takes only a couple of minutes.

Who are the candidates for IUI?

a) couples with unexplained (idiopathic) subfertility of less than 3 years duration
b) couples whose woman's cervical mucous is altered in amount and texture for the sperm to pass through
c) couples who have sex problems such as impotence, premature ejaculation, vaginismus, etc.
d) couples in whom the woman has minimal/mild endometriosis
e) women undergoing insemination with donor sperm

The success rate measured as live birth rate for IUI using fertility drugs (stimulated IUI) is around 18% per treatment cycle and 30-35% after 5 cycles (known as cumulative live birth rate). The cumulative live birth rate for donor insemination is 60-65% after 6 cycles.

Ovulation Induction

It involves the use of fertility drugs to stimulate the development of one or two mature follicles in the ovaries of women who do not develop and release a mature egg every month on their own (oligo- or anovulation). Treatment has the potential to be successful if there are no other causes of infertility. Generally it should be recommended after all relevant infertility investigations have been carried out and irregular ovulation is the only problem. Pregnancy rates per month are around 15-20%, and depend on the age of the woman, the drug used, duration of infertility, other infertility factors. Ovulation induction should be offered for 6-9 months, as the chances that a pregnancy will occur are substantially lower after that.

The most common drugs used for ovulation induction are:
a) clomiphene citrate, which is an oral tablet taken either days 2-6 or 5-9 of the woman's menstrual cycle.
b) injectable gonadotrophins containing follicle stimulating hormone (FSH) and given by intramuscular injection and subcutaneous injections on a daily basis. The injections are started early in the menstrual cycle and are continued for approximately 7-12 days. An injection of human chorionic gonadotrophin (hCG) may be given to induce ovulation once a mature follicle (greater than 17mm in diameter) is seen on scan.

Ovulation induction is somewhat different from controlled ovarian hyperstimulation (COH) which involves the use of the same sort of drugs (administered in the same way) but it is aimed at stimulating the development of multiple mature follicles in order to increase pregnancy rates with IUI/IVF/ICSI treatments. COH helps to get multiple eggs and sperm together either in-vivo (intrauterine insemination) or in-vitro (in vitro fertilisation with or without intra-cytoplasmic sperm injection).

Regular ultrasound monitoring is essential when using injectable gonadotrophins as there are substantial risks associated with over-stimulation if the ovaries over respond to the drug.

Blastocyst Transfer

A blastocyst is an embryo at an advanced stage of development (day 5 post fertilization). With blastocyst transfer, embryos are cultured in the laboratory incubator to the blastocyst stage before they are transferred to the uterus (womb). Potentially using these extra days in culture could help to select the embryos that may have a better potential to implant. It is considered a more natural type of transfer as compared to day 2 or 3 transfer. This is because the blastocyst is transferred to the uterus at almost the same time that it would have entered the uterus should the pregnancy have been spontaneous. Not all embryos will develop to produce blastocysts in the laboratory. Embryos can stop developing at the four-cell stage (day two) and progress no further.

The procedure for blastocyst transfer is identical to that for normal embryo transfer. According to the HFEA data in the UK, the live birth rate with fresh blastocyst transfer is 57.6% for women under 35 years, 50% for women between 35 and 37 years, 38% for women aged between 38 and 39 years, and 33.3% for women aged between 40 and 42 years.

Egg Freezing

Egg freezing can be used successfully for both social and medical reasons. It is becoming more relevant and in demand as many women are facing the real challenge of having successful, healthy pregnancies later in life. This technique offers women planning to have children after the age of 37 the opportunity to effectively slow down their biological clocks by storing their eggs during their reproductive prime. Further, women at risk of premature ovarian failure or those undergoing specific medical treatment that may affect their fertility, such as chemotherapy, radiotherapy or surgical removal of the ovaries, may benefit from egg freezing.

The ovarian stimulation protocol is individualised to maximise the chances of success while reducing the risks, complications and possibly the costs of treatment. Daily fertility drugs (hMG or recombinant FSH or recombinant FSH/LH with or without GnRH agonist or antagonist) are necessary to stimulate the ovaries to produce a high number of oocytes (eggs). The recruitment and development of follicles, which contain the eggs, is tracked by regular transvaginal ultrasound scans and sometimes blood tests. When at least three follicles are mature (greater than 17mm in diameter) a hormone injection (hCG) is given to ripen the eggs. Egg collection is performed 34-36 hours later. The egg collection procedure takes about 20 minutes. Following egg collection, the eggs can be preserved using either the slow-freeze method or the vitrification method (also known as fast-freeze) before storing them in liquid nitrogen at -196 °C for future use. According to the HFEA eggs can be stored up to a period of 10 years which can be extended only in exceptional circumstances. Not all eggs survive the freezing/thawing process. Healthy viable eggs are then fertilised using ICSI.

Egg freezing is still experimental with a small number of births using this method in the UK. The live birth rate using frozen eggs is approximately 15%. Data in the literature show that there is no increase in birth defects or chromosomal abnormalities in children born from frozen eggs.

Egg Sharing

Egg sharing allows a woman to share her eggs (donor) with a woman who needs donated eggs (recipient) to have in vitro fertilisation (IVF) treatment. The egg sharer and recipient usually remain anonymous to each other at the time of treatment, but they may be already known to each other before coming for treatment. The physical characteristics of the women are looked at very carefully and every attempt is made to make the closest match possible. Approval by the recipient will always be required before proceeding to treatment.

The donor undergoes ovarian stimulation as for a conventional stimulated IVF cycle but agrees in advance to donate half of the eggs that she produces during the treatment cycle to a matched recipient. The benefit to the donor will be a much reduced cost of the IVF treatment, whereas the benefit to the recipient will be to use donated eggs to overcome the underlying fertility problem.

Women wishing to enter the egg sharing programme need to meet the following criteria:

• Younger than 35 years
• Body mass index between 20-30 kg/m2
• Non-smoker
• Have no history of viral infections
• Have no personal or family history of genetic diseases
• AMH between 15.8 and 28.7 pmol/l
• AFC greater than 10
• Referred for IVF because of tubal factor or male factor infertility

Genetic Testing

Genetic testing is done to ensure that healthy embryos are selected for transfer in the uterus (womb). Testing the embryos before transfer enables couples who carry a genetic disease to avoid the dilemma of whether to terminate the pregnancy if the created embryo is affected. Embryos created from chromosome imbalanced eggs and sperm have little potential for forming a normal viable pregnancy, but cannot be distinguished from normal embryos using standard morphological evaluation.

Pre-implantation genetic diagnosis (PGD)

This sophisticated technique checks embryo for the genes associated with serious genetic diseases such as haemophilia, Duchenne muscular dystrophy, cystic fibrosis and thalassaemia. Once the fertilised egg has undergone further divisions, one or two cells are taken and assessed for specific genetic errors. This allows couples who are at risk of producing a baby with a specific genetic problem to commence a pregnancy knowing that the embryo is unaffected by the condition.
It is recommended to a) women who have had terminations of pregnancy because the baby had a genetic disease, b) couples who already have a child with a genetic disease, and c) couples who we know to be at risk of certain genetic diseases.

Pre-implantation genetic screening (PGS)

This sophisticated technique screens embryos for aneuploidy (loss or gain in the number of chromosomes). Currently there is lack of data in the literature to recommend PGS as a routine procedure as its accuracy remains uncertain based on the fact that less than half of the chromosomes can be screened. However, it may assist the following: a) women older than 37 years who are at a high risk of carrying a baby with chromosomal abnormalities, for example Down's syndrome, b) women with history of recurrent miscarriage (three or more consecutive early pregnancy losses), and c) couples who have had several failed IVF treatments.

Array Comparative Genomic Hybridisation (Array CGH)

This technique allows regions on every chromosome to be analysed for aneuploidies (number of chromosomes) compared with current techniques that are restricted to specific chromosomal defects. CGH is able to screen the entire chromosome complement (23 chromosomes) in oocytes (eggs) and embryos. Array CGH has two main advantages over other methods of screening: the first is "gene chip" technology that tests DNA very quickly, so that embryos do not need to be frozen while they are checked. The second is that instead of removing cells from embryos, which can damage them, it relies on testing the eggs, which are the cause of 85 per cent of chromosomal defects. The reliability and accuracy of CGH has to be tested rigorously in properly designed trials before it can be concluded that this new technique offers a real benefit in higher take home baby rates. However, data from IVF cycles employing CGH appears to indicate a dramatic increase in embryo implantation following comprehensive chromosomal screening.

Genetic tests for male infertility

Genetic blood tests in male individuals with abnormal semen parameters and infertility provide useful information about DNA, such as whether extra chromosomes are present, chromosomes are lost or rearranged, or large portions of DNA are missing. Abnormalities like these can influence negatively male fertility and the health of an embryo.

Y microdeletions - Approximately 10-20% of men with no sperm and 5% of men with very reduced sperm counts may be missing small parts of the Y chromosome, which carries genetic information required for the formation and function of the testes.

Cystic fibrosis (CF) testing - Cystic fibrosis is the most common life-threatening genetic disease in the Caucasian population, affecting approximately 1 in 2000 live births. Mutations of the CF gene are associated with abnormalities of the male reproductive tract, such as the absence of the vas deferens, or unexplained obstruction of the epididymis.

Sperm DNA Fragmentation - The genetic integrity of the sperm is essential for normal embryo development. A high level of DNA fragmentation in sperm cells may represent a cause of male infertility that conventional semen analysis - sperm concentration, motility analysis, morphology assessment - cannot detect. Results reported in the recent literature have shown that regardless of the assisted reproductive technology used, an elevated level of DNA fragmentation above the critical threshold may compromise the possibility of a successful pregnancy.
Normal, healthy pregnancies do occur in couples where the male partner has a high percentage of sperm with fragmented DNA, although the chances are significantly reduced, as the percentage of sperm bearing low levels of DNA fragmentation is much lower. Embryos derived from sperm whose DNA is highly fragmented have a poor prognosis. Evidence suggests that this could result in initiation of apoptosis (process of natural cell death) and mutations resulting in blastocyst arrest, miscarriage, abnormalities in the offspring and an increased susceptibility to childhood cancer. Protection against high DNA fragmentation may be afforded by younger eggs which are much more efficient at DNA repair of defective sperm than older eggs, so a couple coming for assisted conception treatment where the sperm DNA fragmentation level is high has a better prognosis if his partner is young.
Initial studies suggest that DNA damage occurs at the post-testicular level, so that testicular sperm may have a healthier DNA integrity than ejaculated sperm.
The sperm DNA Fragmentation test involves staining the sperm cells with a fluorescent probe that interacts with the DNA molecule. The fluorescence signal changes when the DNA is fragmented, and this is monitored using a flow cytometer.

Sperm aneuploidy - Approximately 2-13% of all sperm are genetically abnormal in normally fertile men. There is evidence that this percentage may be increased in men who are subfertile. Studies have shown a relationship between poor sperm parameters and increased sperm aneuploidy (chromosomal abnormalities in the sperm). There is no direct correlation between sperm morphology and aneuploidy, and indeed, sperm aneuploidy can also be found in sperm with normal morphology. However, particular types of morphological defects may be linked to a significant increase in sperm aneuploidy rate.
Recent studies have shown that sperm with a high rate of aneuploidy have a negative impact on pregnancy rate and are associated with recurrent miscarriage.

Photogallery

Please view the photogallery for more information on Assisted Conception
    Arrange an Appointment Clinic Locations Other Useful Websites